VACCINEX INC (VCNX) Stock Price, Quote, News and Overview
NASDAQ:VCNX - Nasdaq - US9186403013 - Common Stock
VCNX Quote and Key Statistics
VACCINEX INC
NASDAQ:VCNX (12/17/2024, 9:35:36 PM)
After market: 1.3211 -0.09 (-6.3%)1.41
-2.24 (-61.37%)
VCNX Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -382.72% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
VCNX Performance and Technical Analysis
VCNX Ownership and Analysts
VCNX Latest News and Analysis
Vaccinex Faces Nasdaq Delisting: What's Going On With The Stock?
Vaccinex, Inc. (NASDAQ: VCNX) shares are trading lower after the company announced it received a delisting notification from Nasdaq. Here's what you need to know.
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
ROCHESTER, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company...
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Actively Exploring Partnership for Alzheimer’s DevelopmentSupplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) --...
About VCNX
Company Profile
Vaccinex, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Rochester, New York and currently employs 37 full-time employees. The company went IPO on 2018-08-09. The firm is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimer’s disease, head and neck, pancreatic and breast cancer. Its lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including cancer. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.
Company Info
VACCINEX INC
1895 Mount Hope Ave
Rochester NEW YORK 14620 US
CEO: Maurice Zauderer
Employees: 39
Company Website: https://www.vaccinex.com/
Phone: 15852712700
VCNX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.06 | 305.03B | ||
| AMGN | AMGEN INC | 14.3 | 147.72B | ||
| GILD | GILEAD SCIENCES INC | 20.98 | 115.85B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 839 | 110.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.14 | 75.58B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.18B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.28B | ||
| NTRA | NATERA INC | N/A | 22.11B | ||
| BIIB | BIOGEN INC | 8.63 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 16.43B |